Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Corman, 2012, Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction, Euro Surveill, 17, 10.2807/ese.17.39.20285-en Bak, 2018, An atypical case of Middle East Respiratory syndrome in a returning traveler to Korea from Kuwait, J Korean Med Sci, 33, e348, 10.3346/jkms.2018.33.e348 Oh, 2018, Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea, Korean J Intern Med, 33, 233, 10.3904/kjim.2018.031 Coleman, 2017, MERS-CoV spike nanoparticles protect mice from MERS-CoV infection, Vaccine, 35, 1586, 10.1016/j.vaccine.2017.02.012 Malczyk, 2015, A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform, J Virol, 89, 11654, 10.1128/JVI.01815-15 Muthumani, 2015, A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates, Sci Transl Med, 7, 10.1126/scitranslmed.aac7462 Wang, 2015, Evaluation of candidate vaccine approaches for MERS-CoV, Nat Commun, 6 Choe, 2017, MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015, Emerg Infect Dis, 23, 1079, 10.3201/eid2307.170310 Payne, 2016, Persistence of antibodies against Middle East respiratory coronavirus, Emerg Infect Dis, 22, 1824, 10.3201/eid2210.160706 Zhao, 2017, Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses, Sci Immunol, 2, 10.1126/sciimmunol.aan5393 Luke, 2016, Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo, Sci Transl Med, 8, 10.1126/scitranslmed.aaf1061 Pascal, 2015, Pre- and postexposure efficacy of fully immunized antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection, PNAS, 112, 8738, 10.1073/pnas.1510830112 Corman, 2016, Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection, Clin Infect Dis, 62, 477 Park, 2015, Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea, Emerg Infect Dis, 21, 2186, 10.3201/eid2112.151421 Diehl, 2013, Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers, Hum Vaccin Immunother, 9, 2246, 10.4161/hv.24702 Trimble, 2015, Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial, Lancet, 386, 2078, 10.1016/S0140-6736(15)00239-1 Maslow, 2017, Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus, Hum Vaccin Immunother, 12, 2918, 10.1080/21645515.2017.1358325 Bodmer, 2018, Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model, Virology, 521, 99, 10.1016/j.virol.2018.05.028 Munster, 2017, Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic DPP4 mouse model, NPJ Vaccines, 2, 28, 10.1038/s41541-017-0029-1 Haagmans, 2016, An orthopoxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels, Science, 351, 77, 10.1126/science.aad1283 Song, 2013, Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies, J Virol, 87, 11950, 10.1128/JVI.01672-13 Volz, 2015, Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein, J Virol, 89, 8651, 10.1128/JVI.00614-15